Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients

Camillo Porta, Matteo Zimatore, Lucia Bonomi, Ilaria Imarisio, Chiara Paglino, Andrea Sartore-Bianchi, Luciano Mutti

Research output: Contribution to journalArticle

Abstract

Within a single-institution phase II trial, we investigated the antitumor activity of the Raltitrexed-Oxaliplatin combination as second-line therapy for malignant pleural mesothelioma (MPM). Fourteen patients were enrolled and all were assessable for response. The trial was then closed because chemotherapy, though well tolerated, yielded no objective responses. The best response observed was disease stabilization in 4 patients only (28.57%), while the other 10 patients (71.42%) progressed despite treatment. Median time to progression (TTP) was 8 weeks (average: 9.85, range: 7-20), while median overall survival was just 14 weeks (average: 21.69, range: 9-66+).

Original languageEnglish
Pages (from-to)429-434
Number of pages6
JournalLung Cancer
Volume48
Issue number3
DOIs
Publication statusPublished - Jun 2005

Fingerprint

oxaliplatin
Combination Drug Therapy
Therapeutics
Drug Therapy
Survival
raltitrexed
Malignant Mesothelioma

Keywords

  • Malignant mesothelioma
  • Oxaliplatin
  • Raltitrexed
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. / Porta, Camillo; Zimatore, Matteo; Bonomi, Lucia; Imarisio, Ilaria; Paglino, Chiara; Sartore-Bianchi, Andrea; Mutti, Luciano.

In: Lung Cancer, Vol. 48, No. 3, 06.2005, p. 429-434.

Research output: Contribution to journalArticle

@article{5bd514332f0e4fed8429c1b529e37c56,
title = "Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients",
abstract = "Within a single-institution phase II trial, we investigated the antitumor activity of the Raltitrexed-Oxaliplatin combination as second-line therapy for malignant pleural mesothelioma (MPM). Fourteen patients were enrolled and all were assessable for response. The trial was then closed because chemotherapy, though well tolerated, yielded no objective responses. The best response observed was disease stabilization in 4 patients only (28.57{\%}), while the other 10 patients (71.42{\%}) progressed despite treatment. Median time to progression (TTP) was 8 weeks (average: 9.85, range: 7-20), while median overall survival was just 14 weeks (average: 21.69, range: 9-66+).",
keywords = "Malignant mesothelioma, Oxaliplatin, Raltitrexed, Second-line chemotherapy",
author = "Camillo Porta and Matteo Zimatore and Lucia Bonomi and Ilaria Imarisio and Chiara Paglino and Andrea Sartore-Bianchi and Luciano Mutti",
year = "2005",
month = "6",
doi = "10.1016/j.lungcan.2004.11.015",
language = "English",
volume = "48",
pages = "429--434",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients

AU - Porta, Camillo

AU - Zimatore, Matteo

AU - Bonomi, Lucia

AU - Imarisio, Ilaria

AU - Paglino, Chiara

AU - Sartore-Bianchi, Andrea

AU - Mutti, Luciano

PY - 2005/6

Y1 - 2005/6

N2 - Within a single-institution phase II trial, we investigated the antitumor activity of the Raltitrexed-Oxaliplatin combination as second-line therapy for malignant pleural mesothelioma (MPM). Fourteen patients were enrolled and all were assessable for response. The trial was then closed because chemotherapy, though well tolerated, yielded no objective responses. The best response observed was disease stabilization in 4 patients only (28.57%), while the other 10 patients (71.42%) progressed despite treatment. Median time to progression (TTP) was 8 weeks (average: 9.85, range: 7-20), while median overall survival was just 14 weeks (average: 21.69, range: 9-66+).

AB - Within a single-institution phase II trial, we investigated the antitumor activity of the Raltitrexed-Oxaliplatin combination as second-line therapy for malignant pleural mesothelioma (MPM). Fourteen patients were enrolled and all were assessable for response. The trial was then closed because chemotherapy, though well tolerated, yielded no objective responses. The best response observed was disease stabilization in 4 patients only (28.57%), while the other 10 patients (71.42%) progressed despite treatment. Median time to progression (TTP) was 8 weeks (average: 9.85, range: 7-20), while median overall survival was just 14 weeks (average: 21.69, range: 9-66+).

KW - Malignant mesothelioma

KW - Oxaliplatin

KW - Raltitrexed

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=18844403354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844403354&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2004.11.015

DO - 10.1016/j.lungcan.2004.11.015

M3 - Article

C2 - 15893013

AN - SCOPUS:18844403354

VL - 48

SP - 429

EP - 434

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -